secwatch.observer — SEC 8-K summary
======================================

Issuer:     GoodRx Holdings, Inc. (GDRX)
CIK:        0001809519
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005068
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GoodRx Q4 revenue $184.1M beats guidance; Adjusted EBITDA margin 26.9% exceeds expectations
--------------------------------------------------------------------------------

- Q4 revenue $184.1M, above guidance; net loss $2.01M (includes $29.4M stock-based comp).
- Adjusted EBITDA $49.6M (26.9% margin), exceeding guidance; Adjusted Net Income $27.4M (14.9% margin).
- Full year 2022 revenue $766.6M; Adjusted EBITDA $213.5M (27.8% margin).
- Subscription offerings grew 42% YoY; over 7M consumers of prescription-related offerings.
- Co-CEO cites strong subscription growth and efficiency improvements; 900K prescribers active.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1809519/000095017023005068/0000950170-23-005068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1809519/000095017023005068/gdrx-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer